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S UMMA R Y
S E T T I NG : The detection of multidrug-resistant tuber-
culosis (MDR-TB) using rapid drug susceptibility testing
(DST) has increased steadily in recent years in Peru, from
9216 tests in 2010 to 27 021 tests in 2015. Research
examining the impact of rapid DST on treatment
outcomes is required.
OB J E C T I V E : To evaluate the association between rapid
DST use (nitrate reductase assay, microscopic observa-
tion drug susceptibility assay [MODS] and GenoTypew
MTBDRplus) and treatment outcomes and mortality in
MDR-TB patients in Peru.
DE S I GN : Retrospective cohort study of patients diag-
nosed with pulmonary MDR-TB between 2010 and
2013 (with treatment outcomes up to December 2015)
using the electronic registry of the Peruvian National TB
Programme.
R E SU LT S : A total of 2671 MDR-TB patients were
included; the median age was 27 years, 2.8% were co-
infected with the human immunodeficiency virus. Use of
rapid DST was associated with a 40% increase in the
adjusted odds of treatment success (aOR 1.40, 95%CI
1.19–1.64) and a 54% reduction in mortality (aOR
0.46, 95%CI 0.33–0.64). Higher treatment success rates
were driven by MODS and GenoTypew MTBDRplus
testing (aORs for unsuccessful outcomes respectively
0.68 and 0.66).
CONC LU S I ON : The use of rapid DST (MODS and
MTBDRplus) to diagnose MDR-TB was associated
with a reduction in the odds of death and a substantial
increase in the odds of treatment success.
K E Y WO R D S : outcomes; death; rapid DST; Peru;
operational research
WHILE MOST TUBERCULOSIS (TB) cases can be
cured, the disease remains one of the biggest
infectious disease threats worldwide. In 2015, there
were an estimated 10.4 million new TB cases, 1.4
million of whom died. In addition, of the estimated
580 000multidrug-resistant TB (MDR-TB; defined as
resistance to at least isoniazid and rifampicin) cases
worldwide, only about 20% were detected and
reported, and only 52% of MDR-TB patients had a
successful treatment outcome.1,2
Peru has the highest number of MDR-TB patients
in the Americas Region.3 Although the Lima and
Callao Regions have only one third of the country’s
population, they account for 59% of patients with
susceptible TB, 70% of those with MDR-TB and
73% of those with extensively drug-resistant TB
(XDR-TB; defined as MDR-TB plus resistance to at
least one fluoroquinolone and at least one of the
second-line injectables).4 Treatment and care of
MDR- and XDR-TB leads to increased health care
costs, which must be borne by Peru’s Ministry of
Health (MoH), and leads to economic losses for
patients and their families, adversely affecting their
quality of life.5,6
Early diagnosis, including universal access to drug
susceptibility testing (DST), is one of the key
components of the End TB Strategy championed by
the World Health Organization (WHO) as part of its
new Global TB Strategy post-2015.2 However,
almost one decade before the End TB Strategy, the
Peruvian MoH introduced rapid DST in line with
WHO-recommended policies:7,8 the nitrate reductase
assay (NRA) was introduced in 2006 for all sputum
smear-positive patients,9 in 2008 the microscopic
observation drug susceptibility assay (MODS) was
made universally accessible in those regions where it
was implemented, regardless of smear status,10 and in
2010 the GenoTypew MTBDRplus test (Hain Life-
science, Nehren, Germany) was initially used for
patients with positive microscopy results and MDR-
TB risk factors, but was subsequently made univer-
sally accessible, as set down in the 2013 technical
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guidelines.11 These tests are used to directly detect
MDR-TB from sputum samples with negative or
positive microscopy (MODS) and positive microsco-
py (NRA and MTBDRplus), as well as from culture-
positive samples.10,11
As a result, rapid DST diagnosis increased steadily
in recent years in Peru, from 9216 tests in 2010 to
27 021 tests in 2015.12 However, their implementa-
tion has not been homogeneous. During the study
period, populations will have been served either by a
regional laboratory implementing rapid DST using
MODS, NRA or MTBDRplus, or by a laboratory
earmarked for future upgrading to rapid DST, but
only providing conventional DST using the agar
proportion method (APM) during the study period
following referral of patients who were initially
culture-positive when tested locally. The sequence of
implementation in laboratories and selection of the
rapid DST method to be used was driven principally
by the testing capacity of regional laboratories with
appropriate biosafety measures.13
Few studies have explored the association between
routine rapid DST use and treatment outcomes and
mortality in MDR-TB patients.14,15 NRA use in Peru
has been shown to reduce the time to treatment
initiation,16 while use of MTBDRplus in Georgia has
been associated with reduced time to both MDR-TB
treatment initiation and culture conversion.
Use of XpertwMTB/RIF (Cepheid, Sunnyvale, CA,
USA) in primary health care facilities in South Africa
and Brazil has provided further evidence of the
association between rapid DST use and reduced time
to treatment initiation.14,17 No systematic evaluation
examining the association between the introduction
of rapid DST and treatment success and reduction in
mortality in MDR-TB patients has been conducted in
Peru. Using routine data from available laboratory
records, as well as data on MDR-TB and XDR-TB
treatment, the aim of the present study was to assess
the association between rapid DST use and treatment
outcome and death in MDR-TB patients in Peru from
2010 to 2015.
MATERIALS AND METHODS
This operational research study consisted of a
retrospective analysis of data obtained from the
electronic records of patients classified as having
MDR-TB in Peru’s National Resistant Tuberculosis
Registry (Registro Nacional de Tuberculosis Resis-
tente, RNTR) under the National TB Programme
(NTP), and laboratory records (laboratory informa-
tion system, Netlabw)18 at the Peruvian National
Institute of Health (NIH).19 The RNTR was estab-
lished in 2006 and is the electronic database routinely
used by the MDR-TB Technical Unit of the Peruvian
NTP for monitoring and evaluation of patients
diagnosed with MDR-TB. Data are entered by NTP
data entry staff and checked and validated every week
by the RNTR engineer by cross-checking random
electronic entries with corresponding hard-copy
source data.
The study sample comprised two cohorts of
patients diagnosed with pulmonary MDR-TB from
January 2010 to December 2013 with a documented
treatment outcome in the RNTR up to 31 December
2015. Patients were diagnosed using either 1)
conventional DST only by the Middlebrook 7H10
APM with results from the National TB Reference
Laboratory (NRL) of the Peruvian NIH; or 2) rapid
DST (NRA,MODS,MTBDRplus) with confirmatory
APM testing by the NRL. Patients with an initial
MDR-TB diagnosis on rapid DST that was not
confirmed using subsequent APM testing were
excluded from the study.
Conventional DST was carried out at the Peruvian
NIH TB NRL, which is overseen for external quality
assurance by a supranational reference laboratory.
Rapid DST was performed at the regional reference
laboratories of the national TB laboratory network
and at the NIH TB NRL. The RNTR includes a
treatment outcome for each patient. However, as this
is an operational registry and not specifically de-
signed for research, this information is not always
available; records of patients with no available
treatment outcome in the RNTR were excluded from
this analysis. Definitions used for each treatment
outcome were in accordance with WHO guidelines at
the time of data entry into the database. Time to
MDR-TB treatment initiation and MDR-TB treat-
ment outcome were the study endpoints, with rapid
DST or APM DST alone being the exposures of
primary interest.
Demographic and clinical information was collect-
ed, including year of MDR-TB diagnosis, sex, age,
human immunodeficiency virus (HIV) status and
geographical location. MDR-TB treatment success
was defined as a composite of ‘cured’ cases at hospital
discharge and ‘completed treatment’ status,19 which
provided the number of patients with successful
treatment outcomes among patients diagnosed using
rapid DST vs. APM testing. The treatment success
rate among patients diagnosed using rapid DST was
compared with that of patients diagnosed using APM
with proportional Z test. As a secondary analysis to
propose a predictive model, a dependent variable was
created: success¼1 and no success¼0. Variables with
P , 0.2 were entered into the multivariate logistic
regression model, for which odds ratios (ORs) and
95% confidence intervals (CIs) were reported;
variables with P , 0.05 were considered significant.
Results from the cohort diagnosed using rapid DST
were compared with those from the cohort diagnosed
using APM.
The research protocol was approved by the Ethics
Advisory Group of the International Union Against
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Tuberculosis and Lung Disease, Paris, France, and the
ethics committee of the Hospital Nacional Hipo´lito
Unanue, Lima.
RESULTS
Data from 4758 MDR-TB patients were registered
between January 2010 and December 2013. A total
of 2087 patient records were excluded for the reasons
shown in Figure 1, leaving 2671 MDR-TB patients
who were confirmed by the TB NRL and included in
the analysis. The patients came from all regions of the
country, with a high proportion from the Lima-
Callao Region (75.3%). The male:female ratio was
1.8:1; median age was 27 years (interquartile range
[IQR] 21–37); 93.4% of patients were screened for
HIV, of which 71 (2.8%) were HIV co-infected.
Cohorts
Clinical and epidemiological patient characteristics in
the rapid DST cohort (n¼ 1430) and APM cohort (n
¼ 1241) were similar (Table 1), except that a larger
proportion of the rapid DST cohort were from Lima-
Callao and were diagnosed and treated in the latter
part of the study period.
Time to treatment initiation
Patients in the rapid DST cohort were less likely than
those with only conventional APM testing to initiate
MDR-TB treatment before the DST results became
available (5.2% vs. 39.9% respectively, Figure 2).
The median time to treatment initiation from
availability of DST results in those initiating treat-
ment after DST was available was respectively 21
days (n¼ 1355) and 110 days (n¼ 746) for the rapid
and APM cohorts.
Treatment outcomes
Table 2 shows the treatment outcomes based on year
of treatment initiation and availability of rapid DST
results. The results ‘cured’ and ‘completed treatment’
were combined to obtain the treatment success rate.
Reasons for ‘unsuccessful treatment’, combined and
separated by year, are given in the same table.
Table 2 shows that, year on year, patients for whom
the diagnosis of MDR-TB was made using rapid DST
had a higher treatment success rate than those
diagnosed using slower, conventional methods, in-
creasing to almost 65%, an increase of 10.8% in
treatment success, by 2013 (Z test for comparison of
proportions 0.64 vs. 0.56, P, 0.001). This difference
Figure 1 MDR-TB patient registry, inclusion and exclusion
from the study. Respectively 968, 786 and 717 patients were
tested using NRA, LPA and MODS (some by more than one),
715, 601 and 536 of whom also had a corresponding APM
(reference laboratory) result and were thus eligible for inclusion.
For patients undergoing testing by multiple rapid DST methods,
only the first available test result was used in this analysis,
reflecting the clinical action that ensued. MDR-TB¼multidrug-
resistant tuberculosis; NRA¼nitrate reductase assay; LPA¼ line-
probe assay; MODS¼microscopic observation drug susceptibil-
ity assay; APM ¼ agar proportion method; DST ¼ drug
susceptibility testing.
Table 1 General characteristics of MDR-TB patient cohorts in
Peru, 2010–2013
Rapid DST
cohort*
(n ¼ 1430)
n (%)
APM
cohort†
(n ¼ 1241)
n (%) P value‡
Year of MDR-TB diagnosis
2010 234 (16.4) 388 (31.3) ,0.001
2011 279 (19.5) 367 (29.6)
2012 471 (32.9) 261 (21.0)
2013 446 (31.2) 225 (18.1)
Sex
Female 490 (34.3) 449 (36.2) 0.288
Male 940 (65.7) 792 (63.8)
Age group, years
,15 56 (3.9) 42 (3.4) 0.194
715 and ,35 973 (68.0) 829 (66.9)
735 and ,55 313 (21.9) 266 (21.5)
755 89 (6.2) 103 (8.1)
HIV infection status
No 1319 (92.2) 1104 (88.9) 0.940§
Yes 39 (2.7) 32 (2.6)
Unknown 72 (5.1) 105 (8.5) 0.002¶
Place of origin
Provinces 248 (17.3) 412 (33.2) ,0.001
Capital 1182 (82.7) 829 (66.8)
*Nitrate reductase assay or MODS or GenoTypeW MTBDRplus.
† Conventional DST (proportion method in Middlebrook 7H10 agar).
‡ Calculated using the v2 test.
§Only includes patients with HIV test results.
¶ Includes patients with and without HIV test results.
MDR-TB¼multidrug-resistant tuberculosis; DST¼ drug susceptibility testing;
APM¼agar proportion method; HIV¼human immunodeficiency virus; MODS
¼microscopic observation drug susceptibility assay.
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was largely driven by lower rates of adverse outcomes
death and treatment failure.
Predictors of treatment success
On multivariate analysis, male sex (adjusted OR
[aOR] for treatment success 0.58, 95%CI 0.49–0.69)
and increasing age (aOR 0.79, 95%CI 0.70–0.89)
were associated with unsuccessful treatment. Use of
rapid DST increased the odds of treatment success by
40% (OR 1.4, 95%CI 1.19–1.64). HIV infection
status did not affect the model (Table 3). Greater
treatment success in the rapid DST cohort was
attributable to the effect of MODS (aOR for
unsuccessful outcome 0.68, 95%CI 0.54–0.86) and
MTBDRplus (aOR for unsuccessful outcome 0.66,
95%CI 0.53–0.87). No significant differences were
seen in unsuccessful treatment outcomes between
conventional DST and NRA use (aOR for unsuccess-
ful outcome 0.87, 95%CI 0.70–1.07, P¼ 0.2).
Predictors of death
On bivariate and multivariate analysis, HIV infection
(aOR 1.10, 95%CI 1.04–1.16) and older age (aOR
2.00, 95%CI 1.64–2.44) were associated with death,
while sex was not (Table 4). The odds of death were
significantly greater among patients from regions
outside Lima/Callao (aOR 1.63, 95%CI 1.12–2.36).
Both later years of treatment initiation (aOR 0.80,
95%CI 0.69–0.92) and the use of rapid DST (aOR
0.46, 95%CI 0.33–0.64) were independently associ-
ated with a significant reduction (20% and 54%,
respectively) in the odds of death as the outcome of
MDR-TB treatment.
Impact of confirmatory DST on the effect of rapid DST
Overall, 1082 patients registered as receiving treat-
ment for MDR-TB were excluded from the analysis
(Figure 1). For 496 of these, i.e., 10.4% of all patients
treated with second-line drugs by the NTP during this
period (496/4758), APM DST did not indicate MDR-
TB, likely reflecting empirical treatment preceding
the availability of DST results. MDR-TB treatment
was initiated in 586 patients based on the results of
one of the three rapid DST tests; however, confirma-
tory testing using APM at the NRL was not
performed. To examine if the performance or non-
performance of confirmatory testing introduced bias,
we analysed whether successful treatment outcomes
or death were associated with the performance of
APM DST for each of the rapid DST methods. In the
case of MODS and MTBDRplus (but not for NRA),
the proportion of patients with successful treatment
outcomes was lower, while the proportion of deaths
was higher among those who did not undergo APM
testing (Table 5).
Figure 2 Frequency distribution of time elapsed between DST result availability and MDR-TB
treatment initiation. Patients who started empirical treatment pending the DST result are shown in
red. DST ¼ drug susceptibility testing; APM ¼ agar proportion method; MDR-TB ¼ multidrug-
resistant tuberculosis. This image can be viewed online in colour at http://www.ingentaconnect.
com/content/iuatld/ijtld/2018/00000022/000000011/art00017
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DISCUSSION
The key finding of the present study was that use of
rapid DST inMDR-TB treatment was associated with
a 40% increase in treatment success and a 54%
reduction in the odds of death during MDR-TB
treatment, regardless of the age, sex, place of
residence or HIV status of the patient. This is the
first evidence to suggest that choice of a diagnostic
strategy may impact and improve final treatment
outcomes in MDR-TB treatment, independently of
potential confounders, including temporal trends.
The assumption that reduced time to treatment
initiation leads to improved treatment outcomes
had been difficult to prove until now. These data
appear to substantiate this assertion for the first time.
It has been shown previously that the time to
treatment initiation is significantly reduced upon
introduction of rapid DST in Peru, in the case of both
the NRA16 and MODS.15,20 In Georgia, use of
MTBDRplus has been shown to be associated with
significant clinical improvement, and a reduced time
to MDR-TB treatment initiation and culture conver-
sion.21 The data presented here demonstrate that
Table 2 MDR-TB treatment outcome by DST method and year of treatment initiation
2010 2011 2012 2013 Total
Rapid DST*
(n ¼ 234)
%
APM†
(n ¼ 388)
%
Rapid DST
(n ¼ 279)
%
APM
(n ¼ 367)
%
Rapid DST
(n ¼ 471)
%
APM
(n ¼ 261)
%
Rapid DST
(n ¼ 446)
%
APM
(n ¼ 225)
%
Rapid DST
n (%)
APM
n (%)
Cured 62.0 57.5 47.3 45.0 25.3 24.9 30.7 23.6 533 (37.3) 506 (40.8)
Treatment completed 2.1 2.6 12.2 9.5 39.5 29.9 33.9 30.2 376 (26.3) 191 (15.4)
Failure 9.4 8.5 5.0 5.7 1.9 3.4 5.4 2.2 69 (4.8) 68 (5.5)
Death 7.7 11.1 4.7 11.7 4.2 7.7 3.1 8.9 65 (4.5) 126 (10.2)
Lost to follow-up 18.8 20.4 30.8 28.1 29.1 34.1 26.9 35.1 387 (27.1) 350 (28.2)
Treatment success 64.1 60.1 59.5 54.5 64.8 54.8 64.6 53.8 909 (63.6) 697 (56.2)
Unsuccessful treatment 35.9 39.9 40.5 45.5 35.2 45.2 35.4 46.2 521 (36.4) 544 (43.8)
Total 100 100 100 100 100 100 100 100 1430 (100) 1241 (100)
*Nitrate reductase assay or MODS or GenoTypeW MTBDRplus.
† Conventional DST (proportion method in Middlebrook 7H10 agar).
MDR-TB¼multidrug-resistant tuberculosis; DST¼drug susceptibility testing; APM¼agar proportion method; MODS¼microscopic observation drug susceptibility
assay.
Table 3 Predictors of MDR-TB treatment success
Unsuccessful
treatment
outcome
n (%)
Successful
treatment
outcome
n (%)
Bivariate analysis
OR (95%CI) P value
Multivariate analysis*
aOR (95%CI) P value
Rapid MDR-TB test
No 544 (43.9) 697 (56.1) 1 (Reference) 0.000 1 (Reference) ,0.001
Yes (all) 521 (36.4) 909 (63.6) 1.37 (1.17–1.59) 1.40 (1.19–1.64)
NRA 0.87 (0.70–1.07)
MODS 0.68 (0.54–0.86)
Genotype MTBDRplus 0.66 (0.53–0.87)
Year of MDR-TB diagnosis†
2010 239 (38.4) 383 (61.6) 1 (Reference) 0.721 —
2011 280 (43.3) 366 (56.7)
2012 284 (38.8) 448 (61.2)
2013 262 (39.1) 409 (61.0) 1.01 (0.94–1.09)
Sex
Female 299 (31.8) 640 (68.2) 1 (Reference) 0.000 1 (Reference) ,0.001
Male 766 (44.2) 966 (55.8) 0.59 (0.50–0.70) 0.58 (0.49–0.69)
Age group, years†
,15 24 (24.5) 74 (75.5) 1 (Reference) 0.000 1 (Reference) ,0.001
715–,35 686 (38.1) 1116 (61.9)
735–,55 274 (47.3) 305 (52.7)
755 81 (42.2) 111 (57.8) 0.79 (0.71–0.90) 0.79 (0.70–0.89)
HIV infection status
No 948 (39.1) 1475 (60.9) 1 (Reference) 0.099 —
Yes 37 (52.1) 34 (47.9) 0.97 (0.94–1.01)
Place of origin
Provinces 273 (41.4) 387 (58.6) 1 (Reference) 0.367 —
Capital 792 (39.4) 1219 (60.6) 1.09 (0.91–1.30)
* This model only includes variables independently associated with treatment success (cured, completed treatment).
† OR increase for each category
MDR-TB¼multidrug-resistant tuberculosis; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR; NRA¼ nitrate reductase assay; MODS¼microscopic
observation drug susceptibility assay; HIV¼ human immunodeficiency virus.
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introduction of rapid DST has contributed to
improved outcomes in MDR-TB patients in Peru.
Although logic would suggest that the sooner
adequate MDR-TB treatment is started, the better
the treatment outcome will be, conclusive evidence
has been hard to find. A systematic literature review
conducted in 2016 could not identify a single study
with an adequate methodology to demonstrate an
impact upon MDR-TB treatment outcomes based on
early treatment initiation vs. delayed treatment
initiation.15 The methodology used in the present
study fulfils the search criteria of the earlier review in
showing improved patient-centred outcomes with the
use of rapid DST. However, widespread empirical
treatment led to a result in which half of patients who
only had conventional DST were already receiving
MDR-TB treatment before receiving an appropriate
microbiological diagnosis. The availability of a
laboratory service offering rapid DST may have
encouraged providers to await laboratory confirma-
tion of drug resistance rather than initiate empirical
treatment, which would explain the different distri-
butions of the time to treatment initiation. Empirical
anti-tuberculosis treatment also partially explains
another important evidence gap: despite large-scale
implementation driven by the WHO and other
international agencies as well as widespread research,
conclusive evidence showing that Xpert use has an
epidemiological impact on TB or MDR-TB transmis-
sion remains elusive. Due to the introduction of the
three rapid DST methods reported here, Xpert has
not seen substantial uptake in Peru, and was therefore
not included in this analysis.
Another important observation is that the avail-
ability of a rapid assay alone is not sufficient, as this is
only one component to be considered when assessing
its impact on individual patients and on the commu-
nity. The use of these tests outside established
algorithms and the gap between diagnosis and
treatment initiation may reduce the impact of the
test. Conversely, the use of interventions that close
this gap would be expected to further enhance the
impact of rapid DST. In Peru, universal access to
rapid MODS or MTBDRplus DST remains an
aspiration that has not yet been fully achieved,
although NRA implementation is no longer national
policy. It is not inconceivable that health centres
served by laboratories offering rapid DST provide
better care for TB patients, leading to improved
outcomes (and perhaps better completion of the
RNTR, with patient exclusion being less likely); had
it been feasible, a time-series analysis might have been
able to shed light on this parameter. However, for
some regions, rapid DST became available to health
centres only during the latter part of the study period;
if availability of rapid DST did enhance patient care,
this will have been attributable both to the quick
availability of actionable clinical information (the
Table 4 Factors associated with death in MDR-TB patients
Characteristics
Bivariate analysis
OR (95%CI)
Multivariate analysis*
aOR (95%CI)
Rapid MDR-TB test
No 1 (Reference) 1 (Reference)
Yes (all) 0.42 (0.30–0.57) 0.46 (0.33–0.64)
NRA 0.56 (0.37–0.84)
MODS 0.39 (0.23–0.65)
GenoTypeW MTBDRplus 0.32 (0.19–0.53)
Year of MDR-TB diagnosis†
2010 1 (Reference) 1 (Reference)
2011
2012
2013 0.77 (0.67–0.88) 0.80 (0.69–0.92)
Sex
Female 1 (Reference) –
Male 1.14 (0.83–1.56)
Age group, years†
,15 1 (Reference) 1 (Reference)
715–,35
735–,55
755 1.96 (1.61–2.39) 2.00 (1.64–2.44)
HIV infection status
No 1 (Reference) 1 (Reference)
Yes 1.09 (1.04–1.15) 1.10 (1.04–1.16)
Place of origin
Provinces 1 (Reference) 1 (Reference)
Capital 1.18 (0.83–1.68) 1.63 (1.12–2.36)
* This model only includes variables independently associated with treatment success (cured, completed treatment).
† OR increase for each category.
MDR-TB¼multidrug-resistant tuberculosis; OR¼odds ratio; CI¼confidence interval; aOR¼adjusted OR; NRA¼nitrate
reductase assay; MODS¼microscopic observation drug susceptibility assay; HIV¼ human immunodeficiency virus.
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DST result) and the action taken by providers in using
it. Both are crucial for evaluating impact.
The retrospective nature of the study and the use of
routinely stored electronic records allowed data from
a large sample of programmatically managed patients
to be analysed. However, there are challenges and
limitations with using programme data. One draw-
back to this design is the lack of certain variables that
were not routinely collected, such as admission
status, diabetes status, previous history of anti-
tuberculosis treatment and certain demographic data.
It should be noted that individuals with no registered
treatment outcome or no confirmatory conventional
DST result in the database were excluded to optimise
the validity of the analysis; this resulted in a loss of
data from respectively 21% and 23% of potential
subjects. This raises two concerns: the risk of
selection bias and the quality of routine data
registration and entry within the NTP. Of the 2687
patients excluded, 28% did not have a confirmatory
test for rapid DST indicating MDR-TB. As confir-
matory testing is part of the NTP algorithm, and
while a small proportion may represent technical
failures in the laboratory, this percentage suggests a
management failure leading to a significant gap that
requires improvements in the health care system;
clearly, these patients could not be included in the
analysis. Furthermore, 24% of excluded patients had
APM testing that did not indicate MDR-TB. This
included patients treated empirically for MDR-TB
based on epidemiological risk assessment (e.g.,
treatment failure, knownMDR-TB contact) in whom
APM DST subsequently demonstrated drug suscepti-
bility, and some patients (likely to be a minority) for
whom the APM DST result was discordant with an
earlier rapid DSTresult. The available data set did not
permit breakdown into these two categories, al-
though the approximately 10% of all patients who
received empirical treatment that turned out to be
unnecessary on later testing reflects the proportion
anticipated; DST discordance should ordinarily lead
to an analysis of discrepancies based on a third test as
part of ongoing quality assurance and improvement.
Moreover, as in the previous scenario, these patients
should be excluded to avoid bias in the results.
Perhaps surprisingly, the failure to perform APM
testing was associated with lower rates of treatment
success and higher rates of death among those
apparently benefiting from rapid DST. Patients might
not undergo APM testing because the local health
care provider is overstretched and does not prioritise
seeking a follow-up sample (necessary for GenoType
MTBDR, although not for MODS or NRA, which
both yield a primary isolate), because the culture
becomes contaminated, or because the patient is lost
to follow-up before a second sample can be obtained;
some of these factors may also be associated with
worse treatment outcomes. Further prospective stud-
ies are needed to better understand the mechanisms
underlying this observation.
Finally, among excluded patients, 48% did not
have treatment outcome data available in the register.
This finding shows another systemic failure of
recording that needs to be addressed, while reminding
clinical service providers of the importance of having
reliable routine data. However, there are no reasons
to believe that this lack of information would be any
more common in patients with or without rapid DST,
suggesting that the possibility of significant bias
arising from their exclusion would be minimal.
This was a nationwide operational study spanning
a 5-year period from 2010 to 2015. Based on the
extensive coverage and the amount of data included,
the results provide an important and relevant
message. Temporal changes inMDR-TBmanagement
clearly contribute; however, on multivariate analysis,
the highly positive effect of rapid DST use was
independent of the year of treatment.
In summary, in a country with high rates of MDR-
TB, rapid DST implementation as a routine test was
associated with a significant and important increase
in the odds of treatment success and a major
reduction in the odds of death as an MDR-TB
Table 5 Association between APM DST and treatment
outcomes and death
Treatment outcome
Total
n (%) P value*Success
No
success
NRA
APM
Yes 479 236 715 (67.0)
No 165 88 253 (65.2) 0.64
MODS
APM
Yes 383 153 536 (71.5)
No 108 73 181 (59.7) 0.004
Genotype MTBDRplus
APM
Yes 416 185 601 (69.2)
No 110 75 185 (59.5) 0.016
Death
Total
n (%) P value*Yes No
NRA
APM Total
Yes 46 669 715 (6.4)
No 18 235 253 (7.1) 0.77
MODS
APM
Yes 27 509 536 (5.0)
No 20 161 181 (11.0) 0.008
Genotype MTBDRplus
APM
Yes 30 571 601 (5.0)
No 18 167 185 (9.7) 0.023
*Derived from Fisher’s exact test.
APM ¼ agar proportion method; DST ¼ drug susceptibility testing; NRA ¼
nitrate reductase assay; MODS¼microscopic observation drug susceptibility
assay.
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treatment outcome. These results reinforce the policy
of universal access to rapid DST in Peru; other
countries should explore rapid DST implementation
in the NTP to improve MDR-TB patient health care.
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R E´ S U M E´
C O N T E X T E : La de´tection de Mycobacterium
tuberculosis multire´sistant (TB-MDR) graˆce a` un test
de pharmacosensibilite´ rapide (DST) a constamment
augmente´ au cours des dernie`res anne´es au Pe´rou (de
9216 tests en 2010 a` 27 021 tests en 2015) ; la
de´monstration de l’impact sur les re´sultats centre´s sur le
patient est requise.
OB J E C T I F : Evaluer l’association entre utilisation du
DST rapide (test de nitrate re´ductase, observation
microscopique des milieux de culture [MODS] et
GenoTypew MTBDRplus) et le re´sultat du traitement
et le de´ce`s chez les patients TB-MDR au Pe´rou.
S CH E´MA : Etude re´trospective de cohorte utilisant le
registre e´lectronique du programme national TB des
patients ayant eu un diagnostic de TB-MDR pulmonaire
(2010–2013), avec les re´sultats du traitement jusqu’a`
de´cembre 2015.
R E´ S U LTAT S : Ont e´te´ inclus 2671 patients TB-MDR,
d’aˆge me´dian 27 ans, 2,8% avec une co-infection au
virus de l’immunode´ficience humaine. L’utilisation du
DST rapide a e´te´ associe´e a` une augmentation de 40%
des chances de succe`s du traitement (OR ajuste´ [ORa]
1,40 ; IC95% 1,19–1,64) et une re´duction de 54% des
de´ce`s (ORa 0,46 ; IC95% 0,33–0,64). L’ame´lioration du
succe`s du traitement a e´te´ obtenue graˆce a` l’effet des tests
MODS et MTBDRplus (ORa pour un re´sultat ne´gatif de
0,68 et 0,66, respectivement).
CONC LU S I ON : L’introduction du DST rapide (MODS
et MTBDRplus) pour le diagnostic de TB-MDR a e´te´
associe´e a` une re´duction des risques de de´ce`s et a` une
augmentation significative des chances de succe`s du
traitement.
R E S UM E N
MA R C O D E R E F E R E N C I A: La deteccio´n de
Mycobacterium tuberculosis multidrogorresistente
(TB-MDR) mediante pruebas ra´pidas de
susceptibilidad a las drogas (DST) ha aumentado
constantemente en los u´ltimos an˜os en el Peru´ (de
9216 pruebas en 2010 a 27 021 en 2015), siendo
necesario demostrar su impacto sobre los resultados
centrados en el paciente.
OB J E T I VO: Evaluar la asociacio´n entre el uso de DST
(ensayo de nitrato reductasa, ensayo de evaluacio´n de la
sensibilidad a fa´rmacos mediante observacio´n
microsco´pica [MODS] y GenoTypew MTBDRplus) y
el resultado del tratamiento y la muerte en pacientes con
TB-MDR en el Peru´.
METODO: Estudio retrospectivo de cohortes utilizando
el registro electro´nico del Programa Nacional de TB de
pacientes diagnosticados con TB-MDR pulmonar
(2010–2013), con resultados de tratamiento hasta
diciembre de 2015.
R E SU LTADOS: Fueron incluidos 2671 pacientes con
TB-MDR, los cuales tuvieron una mediana de edad de
27 an˜os y 2,8% con coinfeccio´n por virus de la
inmunodeficiencia humana. El uso de DST ra´pida se
asocio´ con un aumento del 40% en las probabilidades de
e´xito del tratamiento (OR ajustado [ORa] 1,40; IC95%
1,19–1,64) y una reduccio´n del 54% en el resultado de la
muerte del tratamiento (ORa 0,46; IC95% 0,33–0,64).
Beneficios en el e´xito del tratamiento fue impulsado por
el efecto de las pruebas MODS y MTBDRplus (ORa
para el resultado sin e´xito fue de 0,68 y 0,66,
respectivamente).
CONC LU S I O´ N: La introduccio´n de DST rapida (MODS
y MTBDRplus) para el diagno´stico de TB-MDR se
asocio´ con una reduccio´n en las probabilidades de
muerte y un gran aumento en las probabilidades de e´xito
del tratamiento.
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